RSI drugs
in review
3 min read
Updated 2026-10-29
RSI drugs
In the critically ill: always pair a sedative-hypnotic with a neuromuscular blocker (SCCM 2023, strong). Induction agents don’t differ in mortality or peri-intubation hypotension, so choose on haemodynamics and cut the dose in shock. Rocuronium or succinylcholine are equal choices; sux is out with hyperkalaemia risk. Cisatracurium is the ARDS paralytic.
induction agents
| agent | dose (IV) | haemodynamics | notes |
|---|---|---|---|
| etomidate | 0.2–0.4 mg/kg (usual 0.3); 0.15–0.2 in elderly | few cardiovascular effects, but no less hypotension than other agents in trials | suppresses cortisol and aldosterone (can be prolonged). SCCM suggests against giving steroids just to cover etomidate; label advises caution in sepsis and considering cortisol under severe stress |
| ketamine | 1–2 mg/kg (lower in shock) | sympathomimetic; may still drop BP in catecholamine-depleted shock | bronchodilator; preserves drive |
| propofol | reduce sharply in shock | vasodilation, ↓ contractility → most hypotension | → ICU sedatives |
| midazolam | — | slow onset, hypotension | not a good induction agent |
- no difference between etomidate and other agents for mortality, hypotension or vasopressor use (SCCM 2023, conditional, moderate)
- hypotension after intubation is common whatever the drug: have a pressor running or ready → mechanical ventilation
neuromuscular blockers
| agent | dose | onset / duration | avoid / caution |
|---|---|---|---|
| succinylcholine (depolarising) | 1–1.5 mg/kg (label 0.6, range 0.3–1.1) | ~1 min / 4–6 min | hyperkalaemia; after the acute phase (peak 7–10 days) of burns, major trauma, denervation, upper motor neuron injury; neuromuscular disease (rhabdomyolysis); malignant hyperthermia susceptibility |
| rocuronium (aminosteroid) | 1–1.2 mg/kg for RSI | 60–90 s / 30–60+ min (longer in obesity, hepatic failure) | anaphylaxis (rare); prolonged paralysis means sedation must continue |
| cisatracurium (benzylisoquinoline) | bolus, then infusion ~1–3 mcg/kg/min titrated to train-of-four | slower onset / short; organ-independent elimination (Hofmann) | preferred ARDS infusion (used in the largest trials) |
- sux vs roc (SCCM 2023, conditional): either when sux isn’t contraindicated. First-pass success was similar in the ICU trial (82% vs 84%); the larger non-inferiority trial was inconclusive, and success depends on giving enough rocuronium (≥1–1.2 mg/kg)
- after rocuronium the patient stays paralysed for an hour or more: start sedation and analgesia immediately. Most reports of awareness under paralysis followed longer-acting NMBAs
- ARDS: early severe ARDS only (already deeply sedated, or dyssynchrony despite sedation), boluses or ≤48 h infusion; ESICM recommends against routine continuous infusion → ards
- long-term ICU NMBA infusions → prolonged weakness. Monitor with a nerve stimulator and stop daily where possible
adverse effects
- succinylcholine: K⁺ rise, life-threatening in the at-risk groups above; bradycardia (repeat doses, children); fasciculations, myalgia; ↑ intraocular pressure
- etomidate: myoclonus, adrenal suppression, nausea
- all NMBAs: awareness without sedation; ICU-acquired weakness with prolonged infusions (especially with steroids) → ICU-acquired weakness
Prepared 2026-10-29. Not yet verified — check every number against the sources.